| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/01/2007 | US20070027177 11-(3-fluorophenyl)-9-methoxy-3,4-dihydro-2H-pyrido[1,2-b]isoquinoline-1,6-dione, used as antiarrhythmia agents |
| 02/01/2007 | US20070027176 Compositions for veterinary and medical applications |
| 02/01/2007 | US20070027175 Antineoplastic activities of ellipticine and its derivatives |
| 02/01/2007 | US20070027174 Phenylalanine Enamide Derivatives |
| 02/01/2007 | US20070027173 Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists |
| 02/01/2007 | US20070027172 Crystalline pharmaceutical |
| 02/01/2007 | US20070027171 Cycloalkanepyrrolopyridines as dp receptor antagonists |
| 02/01/2007 | US20070027170 Process for preparing amino crotonyl compounds |
| 02/01/2007 | US20070027169 XIAP-Targeted Prostate Cancer Therapy |
| 02/01/2007 | US20070027168 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
| 02/01/2007 | US20070027167 Use of c-Src inhibitors alone or in combinaton with STI571 for the treatment of leukaemia |
| 02/01/2007 | US20070027166 Pyrazolo pyrimidines useful as aurora kinase inhibitors |
| 02/01/2007 | US20070027164 Agents for treating neurodegenerative diseases |
| 02/01/2007 | US20070027163 Indol-3-y-carbonyl-piperidin and piperazin-derivatives |
| 02/01/2007 | US20070027162 Crystalline and amorphous 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin -1-yl]-propyl}-N-pyridin-2-yl-benzamide hydrochloride |
| 02/01/2007 | US20070027161 Central nervous system disorders, Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease (enhancement of cognitive memory), sleep disorders, feeding disorders such as anorexia |
| 02/01/2007 | US20070027160 Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor |
| 02/01/2007 | US20070027159 Therapeutic agents useful for treating pain |
| 02/01/2007 | US20070027157 Quinoxalinone-3-one derivatives as orexin receptor antagonists |
| 02/01/2007 | US20070027156 Crf antagonists and heterobicyclic compounds |
| 02/01/2007 | US20070027155 Biaryl piperazinyl-pyridine analogues |
| 02/01/2007 | US20070027154 Insecticide for agricultural or horticultural use and method of use thereof |
| 02/01/2007 | US20070027153 Topical skin-protectant and anti-pruritic compositions |
| 02/01/2007 | US20070027152 Topical anti-pruritic compositions and methods of action of same |
| 02/01/2007 | US20070027151 A bi-heterocyclic compound e.g 3-methoxyphenyl)-{6-Morpholin-4-yl-2-[2-(pyridin-2-yloxy)-ethoxy]-9H-purin-8-yl}-amine or other derivatives useful for treating an interleukin-12 overproduction-related disorder such as rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis or diabetes |
| 02/01/2007 | US20070027150 2-Amino-quinazolin-5-ones |
| 02/01/2007 | US20070027149 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors |
| 02/01/2007 | US20070027148 adrenergic blocking agents such as R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylamino]ethyl}-4H-benzo[1,4]oxazin-3-one hydrochloride, used for the treatment of repiratoty system disorders |
| 02/01/2007 | US20070027147 Biarylurea derivatives |
| 02/01/2007 | US20070027146 Methods of treating nervous disorders |
| 02/01/2007 | US20070027145 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases |
| 02/01/2007 | US20070027144 Novel use of cannabinoid receptor agonist |
| 02/01/2007 | US20070027143 Novel substituted 2,3-benzodiazepine derivatives |
| 02/01/2007 | US20070027142 Synthesis of vabicaserin, vabicaserin hydrochloride and derivatives by reacting by reacting a 2,3,3A,4,5,9b-hexahydro-1H-cyclopenta(c)quinoline with a chiralagent, 2-methyl-2-oxazoline; decyclization; alkylation; blocking and deblocking; 5-HT2C agonism; schiophrenia |
| 02/01/2007 | US20070027141 Derivatives of alkylpiperazine and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors |
| 02/01/2007 | US20070027140 {2-[(1-cyclopropylmethyl-6-fluoro-1H-indole-3-carbonyl)-amino]-thiazol-5-ylsulfanyl}-acetic acid, used for treating non-insulin dependent diabetes, dyslipidemia, hyperlipidemia, hypertension, obesity and as dietetics |
| 02/01/2007 | US20070027139 Piperazinyl-quinoline derivatives useful for the treatment of cns disorders |
| 02/01/2007 | US20070027138 Derivatives and analogs of galanthamine |
| 02/01/2007 | US20070027137 Analgesic action and antihyperalgesic action; treatment of cognitive deficits, and of various types of pain; Alzheimer's disease, dementia; 1-Phenyl-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione; 1-Benzyl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione |
| 02/01/2007 | US20070027136 Formulations of anthraquinone derivatives |
| 02/01/2007 | US20070027135 Apoptosis promoters |
| 02/01/2007 | US20070027134 Crystal form of asenapine maleate |
| 02/01/2007 | US20070027133 Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| 02/01/2007 | US20070027132 Containing a benzodiazepine ring; 2-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; Alzheimer's disease and Down's Syndrome; prevent the formation of neurological deposits of amyloid protein |
| 02/01/2007 | US20070027131 N-(2-[N',N'-diethylamino]-5-[N''-(4-fluorophenylsulfonyl)-N''-propargylamino]pyrimidin-4-yl)-4'-(pyrrolidin-1-ylcarbonyloxy)-L-phenylalanine; antiinflammatory, antiarthritic agents |
| 02/01/2007 | US20070027130 Tricyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic |
| 02/01/2007 | US20070027129 Taxane, magnetic moiety and covalent binder for production of magnetic antimitotic agent with higher toxicity to cancer cells than normal cells |
| 02/01/2007 | US20070027128 comprising a drug compound 6 alpha ,9 alpha -Difluoro-17 alpha -[(2-furanylcarbony)oxy]-11 beta -hydroxy-16 alpha -methyl-3-oxo-androsta-1,4-diene-17 beta -carbothioic acid S-fluoromethyl ester; dry powder inhaler; with predictable pharmacokinetic and pharmacodynamic behaviour |
| 02/01/2007 | US20070027127 Treatment of inflammatory oral diseases with a combination of inhibitors of TNF-alpha and immunosuppressive agents |
| 02/01/2007 | US20070027126 E.g., N-[4-(5-cyano-1-methyl-1H-pyrrol-2-yl)phenyl]propane-1-sulfonamide and tert-butyl 2-cyano-5-{4-{(ethylsulfonyl)amino]phenyl}-1H-pyrrole-1-carboxylate; useful for contraception and hormone replacement therapy |
| 02/01/2007 | US20070027125 Cyanopyrrole-phenyl progesterone receptor modulators and uses thereof |
| 02/01/2007 | US20070027124 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| 02/01/2007 | US20070027123 Administering an estrogen receptor for treatment of osteoporosis, breast cancer, hypercholesteremia, hyperlipidemia or artheriosclerosis by administering estrogen modulators |
| 02/01/2007 | US20070027122 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| 02/01/2007 | US20070027121 Method of treatment of diarrhea-predominant IBS in a female subject receiving contraceptive therapy |
| 02/01/2007 | US20070027120 Intermittent administration allows high doses of vitamin D compounds (calcitrol) to be administered while minimizing or eliminating hypercalcemia |
| 02/01/2007 | US20070027119 Antibacterial composition and method of use |
| 02/01/2007 | US20070027118 Novel compounds of amino sulfonyl derivatives |
| 02/01/2007 | US20070027117 Novel glucocorticoid receptor ligands for the treatment of metabolic disorders |
| 02/01/2007 | US20070027116 Therapeutic phosphonate derivatives |
| 02/01/2007 | US20070027115 Triazole derivatives useful in therapy |
| 02/01/2007 | US20070027114 cancer and/or viral infection, leukemia; improved pharmacological properties; oral bioavailability, greater potency, extended half-life in vivo, Side effects reduction; 2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6-diethoxy-phosphoryl)-hexanoic acid, diethyl cyano phosphonate |
| 02/01/2007 | US20070027113 Purine nucleoside phosphorylase inhibitory phosphonate compounds |
| 02/01/2007 | US20070027112 Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions |
| 02/01/2007 | US20070027111 Bisphosphate, bis-quaternary ammonium or bis-amine salt compounds that bind a Toll-like receptor; use desensitizing allergies, asthma, treating autoimmune diseases, and inflammatory diseases, ischemia |
| 02/01/2007 | US20070027110 Double salts of (-)-hydroxycitric acid with an amine and a group II a metal and a process for preparing the same |
| 02/01/2007 | US20070027109 Prevent infections using sulfated polysaccharides |
| 02/01/2007 | US20070027108 Method of producing effective bacterial cellulose-containing formulations |
| 02/01/2007 | US20070027107 Compositions and methods for treating estrogen-dependent diseases and conditions |
| 02/01/2007 | US20070027106 Charged sophorolipids and sophorolipid containing compounds |
| 02/01/2007 | US20070027105 Peroxide removal from drug delivery vehicle |
| 02/01/2007 | US20070027104 Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
| 02/01/2007 | US20070027101 Treating ocular neovascular disease using anti-VEGF therapy in combination with a second therapy that inhibits the development of ocular neovascularization or destroys abnormal blood vessels in the eye, such as photodynamic therapy |
| 02/01/2007 | US20070027095 Using nicotinamide riboside-related prodrug for treatment and prevention of cell proliferative disorders |
| 02/01/2007 | US20070027094 Suppresses activity of HMG-CoA reductase; cytokine induction suppressor; lovastatin, mevastatin |
| 02/01/2007 | US20070027093 Anorectic |
| 02/01/2007 | US20070027092 diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, insulin resistance, metabolic syndrome, dyslipidaemias, atherosclerosis, obesity, high blood pressure, chronic heart failure, edema and hyperuricaemia; [4-(5-bromo-2-chloro-benzyl)-phenylethynyl]-triisopropyl-silane |
| 02/01/2007 | US20070027090 Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| 02/01/2007 | US20070027085 Microencapsulation and sustained release of biologically active polypeptides |
| 02/01/2007 | US20070027080 Method for treatment of vitiligo |
| 02/01/2007 | US20070027076 Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| 02/01/2007 | US20070027075 Compositions and methods for targeted drug delivery |
| 02/01/2007 | US20070027067 Transition-state Inhibitors of Pin1, alpha-Ketoamide-containing peptidomimetics, and synthesis thereof |
| 02/01/2007 | US20070027066 Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
| 02/01/2007 | US20070027065 Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
| 02/01/2007 | US20070027064 Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof |
| 02/01/2007 | US20070026494 Mammalian IAP gene family, primers, probes and detection methods |
| 02/01/2007 | US20070026470 Mammalian IAP gene family, primers, probes and detection methods |
| 02/01/2007 | US20070026457 Screening method |
| 02/01/2007 | US20070026450 Methods for the treatment of carcinoma |
| 02/01/2007 | US20070026377 Methods for preserving nucleated mammalian cells |
| 02/01/2007 | US20070026091 Preparation and Administration of Jojoba Product for Reducing Weight, Fat and Blood Lipid Levels and for the Prevention and Treatment of Cancer |
| 02/01/2007 | US20070026090 Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
| 02/01/2007 | US20070026085 Antimicrobial and antiviral composition |
| 02/01/2007 | US20070026081 Microparticles |
| 02/01/2007 | US20070026080 Manufacturing process for tigecycline |
| 02/01/2007 | US20070026079 Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels |
| 02/01/2007 | US20070026077 Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component |
| 02/01/2007 | US20070026075 Gelled donepezil compositions and methods for making and using the same |
| 02/01/2007 | US20070026074 rapidly forms a gel when in contact with sodium or calcium cations in the body for prolonged release of a therapeutic agent; low acyl gellan gum and a phenolic acid; no leakage; antibiotics, fungicides |